Abstract
Immune checkpoint blockade therapies are revolutionizing standard cancer treatments. Immune checkpoint inhibitors likely function to enhance the tumor specific antigen response in order to achieve favorable clinical outcomes. Thus, continuous...
Highlights
In the February issue of Cancer Immunology Research [8], Jhaveri and colleagues used quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer patients treated with allogeneic, granulocytemacrophage colony stimulating factor-secreting pancreatic cancer vaccine (GVAX)
Immune checkpoint blockade enhances the tumor rejection response mediated by these antigens to achieve favorable clinical outcomes
Continuous efforts to identify common tumor-specific antigens are essential for the broad clinical application of these therapies
Summary
In the February issue of Cancer Immunology Research [8], Jhaveri and colleagues used quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer patients treated with allogeneic, granulocytemacrophage colony stimulating factor-secreting pancreatic cancer vaccine (GVAX). Immune checkpoint blockade enhances the tumor rejection response mediated by these antigens to achieve favorable clinical outcomes. It is of importance to identify the right tumor rejection antigens to provide important therapeutic guidance for future cancer immunotherapy.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call